Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

(2016) Gregory J. Dore et al.   ANNALS OF INTERNAL MEDICINE

Rising Mortality Associated With Hepatitis C Virus in the United States, 2003–2013

(2016) Kathleen N. Ly et al.   CLINICAL INFECTIOUS DISEASES

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

(2015) Soumitri Barua et al.   ANNALS OF INTERNAL MEDICINE

Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy

(2013) Natasha K. Martin et al.   CLINICAL INFECTIOUS DISEASES

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

(2013) Natasha K. Martin et al.   HEPATOLOGY

Mixed genotype hepatitis C infections and implications for treatment

(2013) Anna L. McNaughton et al.   HEPATOLOGY

Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011

(2013) J. Iversen et al.   JOURNAL OF VIRAL HEPATITIS

Epidemiology and natural history of HCV infection

(2013) Behzad Hajarizadeh et al.   Nature Reviews Gastroenterology & Hepatology

Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam

(2009) Thijs J.W. van de Laar et al.   JOURNAL OF HEPATOLOGY